{
  "slug": "vitamin-d-deficiency",
  "round": 2,
  "group": 12,
  "date": "2026-10-14",
  "authoring_model": "Sol 6.1",
  "adversarial_reviewer": "Claude Opus 5.5 (Anthropic)",
  "canonical_path": "consensus_consistency_audit_2026-10-09/revised/vitamin-d-deficiency/vitamin-d-deficiency.review.md",
  "edition_note": "Revised edition carrying the 9 October 2026 Consensus consistency validation block; reviewed as it now stands.",
  "divergent_copies_not_touched": [
    "hsef_v53_remaining_priority_01_05_2026-10-09/vitamin-d-deficiency/vitamin-d-deficiency.review.md"
  ],
  "level_before": "Γ",
  "level_after": "Γ",
  "confidence_before": "Moderate",
  "confidence_after": "Moderate",
  "role_before": "epiphenomenon",
  "role_after": "epiphenomenon",
  "pmids_checked": 50,
  "pmids_failed": 0,
  "retractions_or_eoc_found": 0,
  "claims_spot_checked": 12,
  "validator": {
    "before": "PASS — 0 fail, 0 warn, 30 pass",
    "after": "PASS — 0 fail, 0 warn, 30 pass (identical)"
  },
  "findings": [
    {
      "id": "AR-1",
      "severity": "Major",
      "type": "revision_regression_reviewer_notes_contradiction",
      "location": ["REVIEWER NOTES, first paragraph"],
      "original": "No independent blind grading, Consensus, Scite or independent scientific peer review was performed.",
      "corrected": "The same sentence scoped to the original 2026-10-09 review pass, followed by a clause recording that the dated Consensus consistency validation above is a later, separately scoped supplement that changed no grade or source total and is not an independent blinded review either.",
      "evidence": "The known systematic artifact, present in this case. The 9 October integration spliced in a Consensus consistency validation section naming a Consensus Pro thread by URL and listing preserved provider artifacts, while leaving the preserved REVIEWER NOTES sentence denying that any Consensus work was performed. Repaired by scoping the original sentence rather than deleting either block.",
      "level_impact": "none"
    },
    {
      "id": "AR-2",
      "severity": "Major",
      "type": "revision_regression_false_approval_boilerplate",
      "location": ["closing paragraph of the validation block in the review", "consensus-addendum.md"],
      "original": "Its original narrative, registered scope, source inventory, grades and any earlier approval remain historical records; the earlier approval does not certify this supplement.",
      "corrected": "Its original narrative, registered scope, source inventory and grades remain historical records. No earlier adversarial approval is attached to this case, and nothing in the record certifies this supplement.",
      "evidence": "The second clause presupposes an earlier approval although the first hedges it. The earlier edition at hsef_v53_remaining_priority_01_05_2026-10-09/vitamin-d-deficiency/ contains no ADVERSARIAL REVIEW AND APPROVAL section and no adversarial banner.",
      "level_impact": "none"
    },
    {
      "id": "AR-3",
      "severity": "Minor",
      "type": "confidence_justified_by_access_depth",
      "location": ["scorecard final_score.confidence_rationale and its two duplicates"],
      "original": "50 primary reports with 3 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness.",
      "corrected": "Rationale restated on evidence-density and reproducibility grounds, naming the review's own documented reservations and explicitly excluding the reviewer's access depth.",
      "evidence": "Lead two-step test (2026-10-14), and the closest call in this group. Step 1: access depth struck as a determinant. Step 2: band re-derived and retained at Moderate rather than raised to High, because access was not the only thing holding it down. The registered exposure is deficiency while the large trials supplemented broad populations with mostly modest baseline deficiency, so they are indirect for the registered estimand; the one trial recruited in a genuinely deficient population tests a single disease in children; secondary and tertiary reports share parent-trial participants rather than replicating independently; achieved-concentration analyses condition on a postrandomization variable; subgroup and genotype signals are unreplicated; and the Mendelian-randomization evidence carries instrument and nonlinear-stratification assumptions.",
      "level_impact": "none; band unchanged at Moderate"
    },
    {
      "id": "AR-4",
      "severity": "Minor",
      "type": "missing_required_artifact",
      "location": ["Final score block, Divergence line", "scorecard extended_scoring_MSD.divergence.justification"],
      "original": "Contested; no single implied-level arithmetic. No manufactured field consensus or arithmetic gap.",
      "corrected": "Same value, now naming the split: supplement marketing, much of the observational literature and parts of clinical practice framing vitamin-D correction as broadly preventive, against the trialists' reading of their own large randomized nulls (PMID30415629,35026158,40096917,32706534).",
      "evidence": "Divergence is computed, not felt; Contested requires showing a genuine split. Both prose and score card previously asserted only the absence of an arithmetic gap."
    }
  ],
  "rejected_findings": [
    {
      "id": "RJ-1",
      "claim": "The headline should be Delta or Beta.",
      "resolution": "Rejected both. Primary-subclaim is pre-registered and applied as written: SC3 carries the website claim at its stated scope and its Gamma sets the headline, with SC1 (Beta) and SC2 (Gamma) reported without gating, and all three alternatives reported (weakest-link Beta, primary-subclaim Gamma, scope-matched Gamma). Delta fails because no randomized trial delivers a positive across-category incidence effect and the previously significant autoimmune estimate is explicitly superseded. Beta fails because selected genetic findings and disease-specific signals keep the claim above pure association."
    },
    {
      "id": "RJ-2",
      "claim": "Confidence should be High because two very large independent randomized trials converge.",
      "resolution": "Rejected after weighing it explicitly. Those trials are indirect for the registered deficiency estimand, which is an evidence-quality determinant rather than an access one, so the band stands at Moderate."
    },
    {
      "id": "RJ-3",
      "claim": "Momentum is boilerplate.",
      "resolution": "Rejected. The value is already 'Mechanistic only' and the artifact says in terms that the named items are completed reports and that no verified named pending broad deficiency-correction result was found. Exemplary rather than defective."
    },
    {
      "id": "RJ-4",
      "claim": "'Best-supported rival' prints the nominal model (the renderer bug reported elsewhere this round).",
      "resolution": "Rejected; checked and absent. models_evaluated[0] is is_nominal false at rank 1 (Risk marker with selective causal effects); the nominal (Broad deficiency-driven nonskeletal disease) sits at rank 2."
    },
    {
      "id": "RJ-5",
      "claim": "The causal role is wrong.",
      "resolution": "Rejected. 'epiphenomenon' is reached at step 2 of the derivation procedure, and the review records it as an unresolved general role rather than an assertion of biological irrelevance, with skeletal physiology explicitly outside the graded claim."
    },
    {
      "id": "RJ-6",
      "claim": "A dated fact is wrong as of the stated cutoff.",
      "resolution": "Rejected; the most sensitive item is handled correctly. The originally significant VITAL autoimmune estimate (HR 0.78, 95% CI 0.61-0.99) is not left standing; the review reports the updated randomized-period estimate of HR 0.85 (0.70-1.04) after further case confirmation and refuses to treat the two years of post-intervention observation as continued randomized exposure. The D-Health cancer-incidence null (HR 1.02, 0.95-1.10), the D-Health cardiovascular composite crossing no effect, the D2d primary miss and the Mongolian schoolchildren tuberculosis null are all stated accurately and at the right scope."
    },
    {
      "id": "RJ-7",
      "claim": "Trial reports are double counted.",
      "resolution": "Rejected; handled carefully. The four D-Health outcome reports and the VITAL secondary analyses are grouped by study key rather than by paper, and the validation block states that the provider bibliography established no new independent primary trial and that totals remain 50 reports and 54 verified claims."
    },
    {
      "id": "RJ-8",
      "claim": "Reference years disagree with PubMed.",
      "resolution": "Rejected per convention. References 1 (2018/2019), 8 (2013/2014) and 46 (2020/2021) differ from the PubMed e-pub year by one."
    },
    {
      "id": "RJ-9",
      "claim": "Collective-author defect, empty DOI fields, 'PMIDnot supplied', fused numeral tokens or retrieval artifacts present.",
      "resolution": "Rejected; screened across all 50 references, the timeline and the evidence cards and none present."
    }
  ],
  "residual_limitations": "Only three originals were read at partial-body depth, so several quoted effect estimates (the VITAL cancer and cardiovascular hazard ratios, the D-Health composite and myocardial-infarction estimates, and the updated autoimmune confidence interval) rest on the review's own declared partial-body receipts. The raw Consensus browser response named in the validation block was not available to this reviewer, so its provenance claims were checked only for internal consistency.",
  "propagation_strings_for_lead": [],
  "approval": "Approved as revised. — Claude Opus 5.5 (Anthropic), 2026-10-14."
}